Durham, NC - Male Contraceptive Initiative (MCI), a private non-profit foundation, announced five grants, including a grant to Eppin Pharma Inc to support research and development of a male contraceptive, raising MCI’s total commitment to male contraception to over $5M USD since 2017.
Eppin Pharma will receive $300,000 to aid in their work developing a novel form of male contraception. Eppin Pharma’s product, EP055, is a hormone-free method of contraception that is quickly moving to first-in-human studies. EP055 inhibits sperm motility that is crucial for fertility. The drug is intended to be administered as a pill to men on a daily or on-demand basis, providing protection from pregnancy.
With over $5 million invested in male contraceptive product development, MCI seeks to push male contraceptive research projects towards commercialization. There are a variety of male contraceptive research projects in the drug development pipeline; from early stage screening of drugs to studies that pave the way for early clinical trials, and consistent with their mission, MCI focuses their funding on promising projects within this pipeline like Eppin Pharma’s EP055. MCI’s mission is to facilitate research and development of male contraceptives for people around the world, and to build awareness among researchers, donors and the general public about the demand for and status of novel male contraceptive methods.
Through its funding efforts, MCI has championed this mission in manifold ways: investing in promising product development through this and other rounds of funding, supporting students and young professionals through fellowships and travel grants, and consistently advocating with the public and media for an increased method mix that includes male contraception.
“More and more men are expressing the desire to participate in contraception with their partners. We are confident that the time is right to emphatically get behind the talent and energy in the field in order to achieve a real vision for a contraceptive future,” said MCI Executive Director Heather Vahdat.
Dr. Michael O’Rand, CEO and Co-Founder of Eppin added - “We are grateful for the continued support that MCI has given us and hopeful that this additional investment in our technology will advance the field of male non-hormonal contraception. MCI funding has made a significant difference in our ability to reach our goal of a phase one clinical trial in a timely manner.”
About Male Contraceptive Initiative: Male Contraceptive Initiative works to bring new male contraceptives to market. We accomplish this through direct funding, technical support, research, and advocacy. We believe that couples deserve more contraceptive options and that we offer the biggest potential impact for them by focusing on male contraceptives. It’s time men are given more opportunities to contribute toward family planning.
About Eppin Pharma: Eppin Pharma Inc. of Durham, North Carolina, is an emerging pharmaceutical company focused on developing a safe, effective short-term, non-hormonal oral male contraceptive pill. Eppin Pharma’s lead male contraceptive candidate is a small organic compound (EP055) that binds to EPPIN, a protein on the surface of human sperm, resulting in the loss of sperm motility. This non-hormonal treatment is fast acting and does not affect the production of sperm. Eppin Pharma’s prime mission is to develop a male contraceptive pill that prevents pregnancies with no side effects. Eppin Pharma’s vision is to provide a new male contraceptive that will revolutionize family planning. Please visit their website for more information: https://eppinpharmainc.com/